Isotopia Festival

Isotopia Molecular Imaging today announced the appointment of Todd Hockemeyer as Chief Executive Officer of its newly formed US subsidiary, Isotopia USA

Retrieved on: 
Tuesday, June 20, 2023
GMP, Radioactive waste, Clinical trial, Radiopharmaceutical, Hospital, Patient, Laboratory, Isotope, Microbiology, Medical imaging, Isotopia Festival

Previously, Hockemeyer served in executive leadership roles for Radiomedix's and Zevacor's manufacturing and quality teams, similarly building out radiopharmaceutical facilities.

Key Points: 
  • Previously, Hockemeyer served in executive leadership roles for Radiomedix's and Zevacor's manufacturing and quality teams, similarly building out radiopharmaceutical facilities.
  • Isotopia plans to establish its US isotope manufacturing operations over the next 13 months and anticipates providing GMP-grade Lu-177 n.c.a .
  • For this reason, we have established production proficiency in Israel, Canada, Austria, and now the United States.
  • It is Todd's experience and background that will allow us to establish this U.S. manufacturing operation in a very short time."

Philochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements

Retrieved on: 
Tuesday, December 13, 2022
Molecule, Isotopia Festival, Therapy, Heterotrimeric G protein, Precision medicine, Cytokine, Business, Jaden Philogene-Bidace, Doctor of Philosophy, Nuclear pharmacy, Small molecule, Patient, Isotope, GMP, Disease, Neoplasm, CMO, Antibody, Molecular imaging, FAP, Radiopharmaceutical, Business development, Medical imaging, Pharmaceutical industry, Mercury

OTELFINGEN, Switzerland, SEIBERSDORF, Austria and PETAH TIKVA, Israel, Dec. 13, 2022 /PRNewswire/ -- Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Key Points: 
  • Under these agreements, Isotopia will supply high quality 177 Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23.
  • Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics.
  • The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, 177Lu production site and sterile manufacturing plant, are a well-established platform for manufacturing and collaborations.
  • Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Isotope, Half-life, Peptide, Nuclear pharmacy, Database administrator, Therapy, Safety, Radiation, Molecular imaging, Clovis Oncology, Sarcoma, FDA, FAP, SNMMI, Neoplasm, Antibody, Company, Population, Cancer, Private Securities Litigation Reform Act, Isotopia Festival, EANM, U.S. Securities and Exchange Commission, Program, Patient, Colon, CEO, Oncology, Gallium, Cell, Fibroblast, Radionuclide, NCT, NASDAQ, CAFS, Research, Security (finance), Congress, Mesothelioma, BD, GMP, EMA, View, Drug discovery, TRT, Pharmaceutical industry, Medical imaging

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement further secures our ability to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.
  • Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security, said Keren Moshkoviz, Deputy CEO and BD at Isotopia.

With 5.41% CAGR, Molecular Imaging Market Size to Hit USD 7.3 Billion by 2032 | Future Market Insights

Retrieved on: 
Wednesday, September 14, 2022
Photon, Siemens, Single-photon emission computed tomography, Conditional sentence, Siemens Healthineers, Adoption, Health, Cardiology, Time, Molecular imaging, Gynaecology, Hospital, Philips, Prevalence, Functional neurologic disorder, Acquisition, Growth, Biotelemetry, Isotopia Festival, Industry, Deep learning, Canon Medical Systems Corporation, Lung cancer, PET, Degenerative disease, Cancer, Lung nodule, Bruker, Technology, FMI, Lists of diseases, Market, CT, Diagnosis, SPECT, Health care, Awareness, Lists of countries and territories, Globe, Radiology, Positron emission tomography, CAGR, Agriculture, Medical imaging, Fine chemical, Renewable energy, Software

NEWARK, Del., Sept. 14, 2022 /PRNewswire/ -- The global molecular imaging market is anticipated to value at US$ 7.3 Billion while expanding at a CAGR of 5.41% during the forecast period of 2022-2032. The growth of the market can be attributed to the increasing incidences of chronic illness across the globe.

Key Points: 
  • Growing Adoption of AI-Based Technology in the Healthcare Sector to Expand the Molecular Imaging Market at a CAGR of 5.41% by 2032.
  • In Europe, the molecular imaging market is expected to display a CAGR of 4% during the forecast period.
  • Key Takeaways from the Market Study:
    The global molecular imaging market is expected to secure US$ 4.309 Billion in 2022.
  • Future Market Insights,in its new offering, presents an unbiased analysis of the global molecular imaging market, presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

Proactive news headlines including Westar Resources, KGL Resources, Noxopharm and Eclipse Metals

Retrieved on: 
Tuesday, June 14, 2022
Eclipse, Cream, Well, Hydrogen, Copper, OTCQB, Satellite imagery, GTR, La Paz, Therapy, RAD, DIB, Medical research, Hudson Institute of Medical Research, RC, Gold, KMC, The Side, Ironbark, Blue Vein, Controlled Unclassified Information, KZIA, OZM, Brain, IGU, EPM, CPV, CUI, Defense industrial base, TMR, ASX, NETS, CPH, PAB, Patent, RGP, GLH, Contract, Depository Trust Company, RNA, Green Mountain, Isotopia Festival, Acceleration, TSX, DUN, LCT, DTC, Proactivity, UL, News, Neutrophil extracellular traps, MXR, Growth, GLOBE, NASDAQ, FHE, Certification, MEK, Formerly Used Defense Sites, Uranium, Mining, Medical imaging

Click here

Key Points: 
  • Click here
    Eclipse Metals Ltd (ASX:EPM) has welcomed some pleasing results following recent satellite imagery analysis from the multi-commodity Ivittuut Project in south-western Greenland.
  • Click here
    Medallion Metals Ltd (ASX:MM8) has revealed a significantly expanded resource at the Kundip Mining Centre (KMC), part of the 100% owned flagship Ravensthorpe Gold Project (RGP) in Western Australia.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

Retrieved on: 
Thursday, June 9, 2022
Radiation, SNMMI, Ontario Institute for Cancer Research, Time, Nuclear pharmacy, Society of Nuclear Medicine and Molecular Imaging, CEO, Society, GMP, Multimedia, CDMO, Drug Master File, Patient, DMF, NCE, NEPAD African Western and Southern Networks of Centres of Excellence in Water Sciences, Disease, TEL, Contract, Commercialization, Molecular imaging, Center, Radiopharmaceutical, Network, View, McMaster University, Cancer, Medical imaging, Pharmaceutical industry, Isotopia Festival, BC

Lu-177 has been successfully transferred into CPDC's GMP facility and that CPDC has shipped its first doses of commercial n.c.a.

Key Points: 
  • Lu-177 has been successfully transferred into CPDC's GMP facility and that CPDC has shipped its first doses of commercial n.c.a.
  • Isotopia is thus adding a new production site in North America at CPDC, strengthening its global footprint in the n.c.a.
  • Lu-177 supply in North America" said Dr. Bruno Paquin, CEO of CPDC, "CPDC and Isotopia are proud to offer this unique value proposition for CPDC's clients and beyond, empowering CPDC to become an all-encompassing radiopharmaceutical CDMO."
  • For more information about Isotopia, please visit: www.isotopia.co.il
    The Centre for Probe Development and Commercialization (CPDC) is located in Hamilton, Ontario, Canada.